Detalles de la búsqueda
1.
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Invest New Drugs
; 40(4): 762-772, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35467243
2.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29533458
3.
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
Cancer Res
; 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833522
4.
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Cancer Chemother Pharmacol
; 92(1): 15-28, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37219686
5.
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 14(20)2022 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291780
6.
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Target Oncol
; 17(2): 125-138, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35347559
7.
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Cancer Chemother Pharmacol
; 89(1): 93-103, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34750637
8.
The impact of consenter characteristics and experience on patient interest in clinical research.
Oncologist
; 14(5): 468-75, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19401521
9.
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
Clin Cancer Res
; 25(18): 5458-5465, 2019 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31068369
10.
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Clin Cancer Res
; 25(1): 90-98, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30201761
11.
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
J Clin Pharmacol
; 58(2): 180-192, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28800141
12.
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Clin Cancer Res
; 24(17): 4072-4080, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29764853
13.
Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Target Oncol
; 17(2): 139, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35380379
14.
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 23(18): 5349-5357, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634283
15.
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Clin Cancer Res
; 22(5): 1095-102, 2016 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26581242
16.
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Cancer Discov
; 6(7): 740-53, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27217383
17.
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Cancer Chemother Pharmacol
; 75(1): 183-9, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25417902
18.
Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Clin Cancer Res
; 20(19): 5032-40, 2014 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25107918
19.
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 73(2): 363-71, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297683
20.
Consent timing and experience: modifiable factors that may influence interest in clinical research.
J Oncol Pract
; 8(2): 91-6, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23077435